Company Overview
| Stock Name | Biodlink-B |
|---|---|
| Stock Code | 01875 |
| Company Full Name | To be extracted |
| Industry | 醫療保健 |
| Principal Activities | 主要在中國從事生物制藥業務，專注於開發及商業化創新型腫瘤藥物及療法。 |
| Listing Date | 2019-11-08 |
| Listing Rules Era | Old Rules |
| Listing Rules Chapter | To be extracted |
| Weighted Voting Rights (WVR) | No |
| Registered Address (Mainland China) | 中國江蘇省蘇州市蘇州工業園區長陽街120號 |
| Business Address (Hong Kong) | To be extracted |
| Place of Incorporation | To be extracted |
| Listing Method | To be extracted |
| Listing Board | Main Board |
| Website | https://www.biodlink.com/ |
| Share Registrar | 卓佳证券登记有限公司 (Tricor Investor Services Limited) |
| Registrar Contact | (852)2980 1333 |
| A-Share/US Dual Listing | No data |
Offering Information
| Offering Mechanism | To be extracted |
|---|---|
| Offer Price | HK$ 6.55 / shares |
| Offer Price Range | To be extracted |
| Lot Size | To be extracted |
| Entry Threshold | To be extracted |
| Par Value | To be extracted |
| Offer Period | To be extracted |
| Global Offering Shares | To be extracted |
| HK Public Offer Shares (Initial) | To be extracted |
| Public Offer Lots (Initial) | To be extracted |
| International Placing Shares (Initial) | To be extracted |
| Offer Ratio | To be extracted |
| Total Shares Post-IPO | To be extracted |
| Greenshoe (Over-allotment Option) | To be confirmed |
| Stabilizing Manager (Greenshoe) | — |
| Cornerstone Share | 26.6% |
| Clawback Tiers | To be extracted |
| Reallocation Option | To be confirmed |
| Total Global Offering Size | HK$ 58,950,000 |
Stock Connect Inclusion
| HK Market Cap | --- |
|---|
| 26Q2 Regular Review | |
| Inclusion Pathway | None |
|---|---|
| Est. Threshold | --- |
| Analysis Result | 无法确定入通路径 |
Valuation & Financials
| Market Cap (at Offer Price) | To be extracted |
|---|---|
| Pre-IPO Valuation (Last Round) | Not disclosed |
| P/E Ratio | Not disclosed |
| Profit/Loss Status | To be extracted |
| Period-End Cash Balance | To be extracted |
| Listing Expenses | To be extracted |
| Listing Expenses / Funds Raised | To be extracted |
| Total Pre-IPO Investment | To be extracted |
First Day Performance
| First Day Close | HK$ 6.26 |
|---|---|
| First Day Open | HK$ 6.43 |
| First Day Change | -4.43% |
| First Day Volume | 26029200.0 |
| First Day Turnover | 165388000.0 |
Use of Proceeds
| Use of Proceeds | 1、約30.0%（或153.5百萬港元）將為TAB008的進行中及計劃進行的臨床試驗、注冊備案準備及潛在商業推出（包括銷售及營銷）提供資金； 2、約50.0%（或255.7百萬港元）將為我們研發中的其他在研藥物的進行中及計劃進行的臨床前及臨床試驗、設施擴充、注冊備案準備及潛在商業推出（包括銷售及營銷）提供資金； 3、約15.0%，或76.7百萬港元將用于非項目指定的資本開支； 4、約2.0%（或10.2百萬港元）將為透過內部研究及外部許可以及業務開發合作，持續擴展癌癥及其他潛在治療領域的產品組合提供資金； 5、約3.0%（或15.3百萬港元）將用于我們的營運資金及其他一般企業用途。 |
|---|
Underwriting Syndicate
Sole Sponsor (1)
ICBC INTERNATIONAL CAPITAL LIMITED CE AQW615
Overall Coordinators (2)
Joint Bookrunners (4)
Joint Lead Managers (6)
ICBC INTERNATIONAL SECURITIES LIMITED CE ARO299
Yuanta Securities (Hong Kong) Company Limited CE ABS015
China Renaissance Securities (Hong Kong) Limited CE AZX839
CHINA EVERBRIGHT SECURITIES (HK) LIMITED CE AAW536
LUK FOOK SECURITIES (HK) LIMITED CE ACU547
HEAD & SHOULDERS SECURITIES LIMITED CE AFS455
Cornerstone Investors
| # | Investor Name | Investment Amount | Shares Subscribed | % of Offer Shares | % of Total Shares | Lock-up Period | Est. Unlock Date |
|---|---|---|---|---|---|---|---|
| 1 | Vivo Funds | 78,366,820 HKD | — | 13.29% | — | 6 months | 2020-05-08 |
| 2 | 年兴国际(维京群岛)有限公司 | 39,182,100 HKD | — | 6.65% | — | 6 months | 2020-05-08 |
| 3 | 晟德大药厂股份有限公司 | 39,182,100 HKD | — | 6.65% | — | 6 months | 2020-05-08 |
Directors & Management
| Chairman | 李錦才 |
|---|---|
| Company Secretary | 呂穎一,陳一帆 |
No director data available.
Major Shareholders
| Major Shareholders & Holdings | Vivo Capital VIII, LLC(28.68%);Center Laboratories, Inc.(28.66%);Chengwei Evergreen Capital, LP(7.39%);Advantech Capital II L.P.(6.42%) |
|---|
